Want to see HK:0858 full AI Analyst Report?
Extrawell Pharmaceutical Holdings Limited (0858) AI Stock Analysis
Extrawell Pharmaceutical Holdings Limited
(HKEX:0858)
Extrawell Pharmaceutical's overall score of 58 is primarily driven by mixed financial performance, with strong profitability and balance sheet stability offset by declining revenue and negative cash flows. A low P/E ratio suggests undervaluation, providing a positive boost, but bearish technical trends indicate caution. Financial performance carries the most weight in this assessment.
Extrawell Pharmaceutical Holdings Limited (0858) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 147.90M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.22M
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.08
- Revenue Growth
- -7.12%
- EPS Growth
- -523.61%
- Country
- Hong Kong
- Employees
- 158
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Extrawell Pharmaceutical Holdings Limited Business Overview & Revenue Model
Company Description
Extrawell Pharmaceutical Holdings Limited, an investment holding entity, specializes in the pharmaceutical sector. Its operations encompass the creation, production, promotion, distribution, and sale of medicinal goods throughout the People's Republi...
How the Company Makes Money
null
Extrawell Pharmaceutical Holdings Limited Financial Statement Overview
Summary
Extrawell Pharmaceutical's financial performance is mixed. Strong profitability margins (Net Profit Margin at 401.67%) and a stable balance sheet (Debt-to-Equity Ratio of 0.11) are positives. However, declining revenue (-7.23% growth) and negative cash flows (Operating Cash Flow of -4.37M) highlight significant risks, leading to a moderate score.
Income Statement
65PositiveBalance Sheet
70PositiveCash Flow
40Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.48M | 51.48M | 55.43M | 59.10M | 72.58M | 73.92M |
| Gross Profit | 22.75M | 22.75M | 21.87M | 28.78M | 31.14M | 37.56M |
| EBITDA | -1.93M | -1.77M | 255.11M | -129.65M | 155.20M | 157.84M |
| Net Income | -979.71M | -979.71M | 222.64M | -162.95M | 129.26M | 130.59M |
Balance Sheet | ||||||
| Total Assets | 587.34M | 587.34M | 1.53B | 1.29B | 1.44B | 1.32B |
| Cash, Cash Equivalents and Short-Term Investments | 214.16M | 214.16M | 994.86M | 95.01M | 123.96M | 135.52M |
| Total Debt | 169.33M | 169.33M | 140.94M | 120.41M | 615.58M | 597.67M |
| Total Liabilities | 207.75M | 207.75M | 191.55M | 174.58M | 671.28M | 659.53M |
| Stockholders Equity | 375.09M | 375.09M | 1.33B | 1.11B | 769.36M | 653.29M |
Cash Flow | ||||||
| Free Cash Flow | -913.00K | 0 | -7.44M | -4.89M | -3.40M | -11.23M |
| Operating Cash Flow | -913.00K | 0 | -4.37M | -3.69M | 3.21M | -1.60M |
| Investing Cash Flow | 680.00K | 0 | -9.38M | 2.04M | -12.50M | -9.63M |
| Financing Cash Flow | 14.54M | 0 | -1.58M | -6.50M | -2.29M | -1.80M |
Extrawell Pharmaceutical Holdings Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0858, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 28.44 is Positive, neither overbought nor oversold. The STOCH value of 22.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0858.
Extrawell Pharmaceutical Holdings Limited Peers Comparison
Overall Rating
HK:095068Neutral
HK:234859Neutral
HK:089758.6Neutral- HK:085858Neutral
HK:045544Neutral
HK:149842Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0950 | 68Neutral | HKD 606.50M | 3.64 | 8.02% | 5.61% | 7.05% | 22.46% |
| HK:2348 | 59Neutral | HKD 1.39B | 5.12 | 6.78% | 6.85% | 6.55% | 36.62% |
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:0858 | 58Neutral | HKD 147.90M | -0.13 | -154.56% | ― | -7.12% | -523.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:0455 | 44Neutral | HKD 191.35M | -2.73 | -14.55% | ― | 12.89% | -2.56% |
| HK:1498 | 42Neutral | HKD 123.04M | -4.04 | -21.66% | ― | -6.71% | 43.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0858 | Extrawell Pharmaceutical Holdings Limited | 0.05 | -0.04 | -44.57% | |
| HK:0455 | Tianda Pharmaceuticals Ltd. | 0.09 | -0.05 | -34.07% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:0950 | Lee's Pharmaceutical Holdings Limited | 1.03 | -0.77 | -42.94% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.23 | -0.19 | -45.24% | |
| HK:2348 | Dawnrays Pharmaceutical Holdings Ltd. | 0.92 | -0.20 | -17.86% |
Extrawell Pharmaceutical Holdings Limited Corporate Events
Extrawell Pharma Weighs HK$715 Million Sale of Starcoin Convertible Bonds
Extrawell Pharmaceutical Holdings has entered into a non-legally binding memorandum of understanding with a potential purchaser regarding the possible sale of all its convertible bonds in Starcoin, with a total principal amount of HK$715 million, and...
Extrawell Pharmaceutical Lifts Stake in Key Subsidiary via Share Buy-Back
Extrawell Pharmaceutical Holdings Limited has completed a share buy-back and cancellation at its 80.46% indirectly owned subsidiary Changchun Extrawell, following fulfillment of all conditions on 16 March 2026. After the transaction, Changchun Extraw...
Extrawell Pharmaceutical Extends Bond Amendment Long Stop Date and Delays Shareholder Circular
Extrawell Pharmaceutical has agreed with bondholder Starcoin to extend the long stop date for completing the fourth set of amendments to its bond terms from 31 March 2026 to 30 June 2026. The change allows more time to satisfy precedent conditions an...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 19, 2025